Home From the Wires Merck & Co. to buy Idenix

Merck & Co. to buy Idenix

| Print |  Email
Monday, June 09, 2014

Reuters: The drugmakers purchased Idenix Pharmaceuticals Inc. for $3.85 billion to boost its hepatitis C drugs portfolio.

Cambridge, Massachusetts-based Idenix, which focuses on the treatment of human viral diseases, has three drugs in development to treat hepatitis C.

An estimated 3.2 million people in the United States are living with chronic hepatitis C infection, with most being unaware of the infection and showing no symptoms, according to the U.S. Centers for Disease Control and Prevention.

Read more here.

 

More Articles

What I'm Reading

October 2014
Thursday, September 25, 2014

Nick Herinckx, CEO of Obility, and Jake Weatherly, CEO of SheerID, share what they've been reading.


Read more...

Report Card

September 2014
Tuesday, August 26, 2014

Strong public schools shore up the economy, survey respondents say. But local schools demonstrate lackluster performance.


Read more...

Powerlist: Law Firms

October 2014
Thursday, September 25, 2014
BY KIM MOORE

A conversation with leading partners at law firms in Portland and eastern Oregon, followed by October's powerlist.


Read more...

Fast Food Slows Down

September 2014
Tuesday, August 26, 2014
BY KIM MOORE

The ubiquitous fast-food restaurant may be on the decline.


Read more...

Podcast: Interview with Pete Friedes

Contributed Blogs
Wednesday, August 27, 2014

082714-thumb friedesbookTom Cox interviews Pete Friedes, author of "The 2R Manager," about becoming a Best Boss.


Read more...

Fork & Bottle

October 2014
Thursday, September 25, 2014

National media can’t get enough of Oregon’s pinot noir, artisan-food purveyors and lively, independent film scene.


Read more...

Two Sides of the Coin

Contributed Blogs
Wednesday, October 22, 2014
22 twosidesBY JASON NORRIS

Historically, when the leaves fall, so do the markets. This year, earnings, Europe, energy and Ebola have in common? Beyond alliteration, they are four factors that the investors are pointing to for this year’s seasonal volatility.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS